Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13810442 | 0.84 | NOS3 (0.40) | NOS3NOS1NOS2TSHR | |
| SCHEMBL18948528 | 0.81 | — | — | |
| SCHEMBL20260142 | 0.79 | NOS3 (0.36) | NOS3NOS1NOS2TSHR | |
| SCHEMBL22363337 | 0.78 | KCNJ1 (0.35) | NOS2TSHR | |
| SCHEMBL10391846 | 0.74 | NOS3 (0.46) | NOS3NOS1NOS2 | |
| SCHEMBL18707729 | 0.74 | NOS3 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL21711086 | 0.73 | MAPT (0.33) | TSHR | |
| SCHEMBL18672330 | 0.73 | HTT (0.41) | NOS3NOS2 | |
| SCHEMBL16414534 | 0.71 | NOS3 (0.48) | NOS3NOS1NOS2 | |
| SCHEMBL31003115 | 0.71 | NOS3 (0.43) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961198-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200131134-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131134-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | NOS3 4473/4885NOS1 4683/4885NOS2 4716/4885 |
| US-10961198-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | NOS3 4473/4885NOS1 4683/4885NOS2 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.